Orchestra BioMed Holdings (OBIO) Stock Forecast: StockMap's 2-Week Call

OBIO stock forecast: StockMap's model makes no two-week call on Orchestra BioMed Holdings after the Nov 19 close: its evidence is split, 7 reasons for and 8 against. Right in 3 of 4 two-week windows on OBIO since Aug 21; by chance, a call on the same dates was right 71% of the time.

Orchestra BioMed Holdings last closed at $7.00, -6.17% on the session.

Against the IVW growth benchmark the position is -3.84% over the forecast window.

Orchestra BioMed Holdings' market cap is $550.91M as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 10 (too close to call).

Where OBIO sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 47%.

13 daily calls for OBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Orchestra BioMed Holdings in the 5th percentile on return on equity, where 100 is best.

Orchestra BioMed Holdings is classified under Health Care / Health Care Equipment & Supplies.

StockMap tracks Orchestra BioMed Holdings as the 72nd largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.

On that composite Orchestra BioMed Holdings ranks 9th of 141 in the group, against a group median of -0.18.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Orchestra BioMed Holdings (OBIO) — StockMap 2-week forecast & tracked accuracy